pharmaphorum June 25, 2025
Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another.
The agreement with Gilead revolves around a molecular glue degrader (MGD) programme targeting CDK2, which is known to contribute to the growth of breast cancer as well as other solid tumours, including some ovarian, endometrial, and gastrointestinal cancers.
The agreement has a top-line value of $750 million, which includes upfront and potential opt-in payments to the tune of $85 million, said Kymera, which will have responsibility for taking the preclinical-stage programme forward for the time being.
While drugs are already in development that target CDK2, Kymera thinks its molecular glue approach, which deploys a small-molecule...
Today's Sponsors
Today's Sponsor